Point Biopharma Global Inc. PNT
We take great care to ensure that the data presented and summarized in this overview for POINT Biopharma Global Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PNT
View allLatest Institutional Activity in PNT
Top Purchases
Top Sells
About PNT
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Insider Transactions at PNT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Yael Margolin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,710
-100.0%
|
-
|
|
Dec 27
2023
|
David Charles Lubner Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,600
-100.0%
|
-
|
|
Dec 26
2023
|
Jonathan R. Goodman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
41,872
-100.0%
|
-
|
|
Dec 26
2023
|
David Charles Lubner Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
35,400
-90.77%
|
-
|
|
Dec 26
2023
|
Rajesh Malik Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,700
-100.0%
|
-
|
|
Dec 26
2023
|
Gerald L. Hogue Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,596
-100.0%
|
-
|
|
Dec 22
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,494,153
-100.0%
|
-
|
|
Dec 22
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,160
-100.0%
|
-
|
|
Dec 22
2023
|
Allan C Silber Executive Chairman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,727,975
-100.0%
|
-
|
|
Dec 22
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
233,529
-100.0%
|
-
|
|
Dec 22
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,773,045
-100.0%
|
-
|
|
Dec 18
2023
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
17,161,278
-100.0%
|
$205,935,336
$12.45 P/Share
|
|
Nov 06
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
120,000
-3.32%
|
-
|
|
Nov 03
2023
|
Allan C Silber Executive Chairman |
SELL
Bona fide gift
|
Indirect |
500,000
-92.92%
|
-
|
|
Oct 31
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
250,000
-8.27%
|
-
|
|
Mar 21
2023
|
Gerald L. Hogue Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,936
+45.37%
|
$107,616
$6.97 P/Share
|
|
Nov 29
2022
|
Joe A. Mccann Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,160
+0.06%
|
$12,960
$6.64 P/Share
|
|
Nov 28
2022
|
Rajesh Malik Director |
BUY
Open market or private purchase
|
Direct |
3,700
+50.0%
|
$22,200
$6.66 P/Share
|
|
Nov 25
2022
|
Gerald L. Hogue Director |
BUY
Open market or private purchase
|
Direct |
3,660
+50.0%
|
$21,960
$6.82 P/Share
|
|
Nov 23
2022
|
David Charles Lubner Director |
BUY
Open market or private purchase
|
Direct |
3,600
+50.0%
|
$21,600
$6.85 P/Share
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 5.31K shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 15.3M shares |
| Open market or private sale | 17.2M shares |
| Bona fide gift | 870K shares |